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Abstract
Despite the successful introduction of potent anti-cancer therapeutics, most of these drugs lead to only modest tumor-
shrinkage or transient responses, followed by re-growth of tumors. Combining different compounds has resulted in
enhanced tumor control and prolonged survival. However, methods querying the efficacy of such combinations have been
hampered by limited scalability, analytical resolution, statistical feasibility, or a combination thereof. We have developed a
theoretical framework modeling cellular viability as a stochastic lifetime process to determine synergistic compound
combinations from high-throughput cellular screens. We apply our method to data derived from chemical perturbations of
65 cancer cell lines with two inhibitors. Our analysis revealed synergy for the combination of both compounds in subsets of
cell lines. By contrast, in cell lines in which inhibition of one of both targets was sufficient to induce cell death, no synergy
was detected, compatible with the topology of the oncogenically activated signaling network. In summary, we provide a
tool for the measurement of synergy strength for combination perturbation experiments that might help define pathway
topologies and direct clinical trials.
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Introduction
The vision of personalized cancer medicine has recently become
an achievable goal through the development of novel cancer
therapeutics and the link of their efficacy to somatic genetic
aberrations (or, ‘‘lesions’’). Prominent examples are ERBB2-
amplified breast cancers [1] that respond to ERBB2 inhibition,
BCR-ABL-translocated chronic myeloid leukemia patients that
can be successfully treated with the ABL kinase inhibitor imatinib
[2,3], or EGFR-mutant non-small cell lung cancers (NSCLC) that
are sensitive to treatment with the EGFR inhibitors erlotinib and
gefitinib [4]. However, the enthusiasm about this success has been
dampened by limited tumor shrinkage in most patients and the
occurrence of relapse after an initial response [5,6,7,8,9,10].
The concept of simultaneous targeting of more than one signaling
pathway or pathway component has been pursued for manyyears as
a promising strategy to increase treatment efficacy or prevent the
emergence of drug resistance [11,12,13]. In the area of conventional
cytotoxic chemotherapy, only the combination of multiple drugs has
enabled actual cures for leukemia and lymphoma patients [14].
Additional examples include the successful combination of thera-
peutic antibodies and chemotherapy for treatment of lymphomas, as
well as breast and colorectal cancer [15,16]. Finally, combining
specific inhibitors of oncogenic signaling pathways has resulted in
highly synergistic treatment responses in clinically relevant tumor
models [17,18,19]. Thus, systematic approaches to interrogate
synergistic compound combinations and to link these to individual
genetic lesions are required to move these combinations into clinical
trials more rapidly. Another notion supporting the systematic study
of such combination therapies comes from the careful biochemical
dissection of oncogenicsignaling pathways:itwasshown thatmostof
these pathways are interconnected by feedback loops [20,21,22].
Thus, simultaneously blocking two or more of such pathways might
lead to activation of the alternate pathway by release of negative
feedback loops. Accordingly, beyond the obvious benefit for drug
discovery,suchstudiesmayhelpdefiningsignalingpathwaytopology
connected with individual genetic lesions.
Unfortunately, establishing synergistic compound combinations
at greater scale is typically hampered by the necessity to screen
multiple compound concentrations of one compound against
different concentrations of another compound. Furthermore,
many analytical approaches do not consider continued prolifer-
ation of viable cells and do not afford establishing statistically
meaningful representations of screening data across a broad
experimental range.
Several methods for the detection of compound synergy have
been proposed [23,24,25,26]. In summary, the diverse definitions
of synergy and methods for its detection are based on two
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However, a precise methodological derivation of the analytical
procedure and the close adaptation to an experimentally tractable
setup amenable to high-throughput cellular screening have been
lacking so far. We therefore set out to develop both a novel
approach for high-throughput cell-based screening of multiple
compound concentrations and a statistical framework to define
synergy as a probabilistic lifetime process under single and
combined chemical perturbations. We applied this model to
screening data derived from a screen of a panel of genetically and
phenotypically characterized NSCLC cell lines and determined
global genetic settings in which synergy of the irreversible EGFR/
ERBB2 inhibitor BIBW-2992 and a dual PI3K/mTOR inhibitor
PI-103 is most pronounced.
Results
Population-Based Analysis of Cell Viability Measurements
We reasoned that cellular dose response that is commonly used
for cell viability measurements is based on a change of the cellular
growth rate when a given perturbation (in most cases, a chemical
compound) is added in comparison to untreated cells. This
description allows a probabilistic interpretation in terms of a
stochastic waiting-time process. For a given compound concen-
tration x, these ideas lead to the following relationship
v(x)~exp {lt 1{
1
1z x=K ðÞ
m
     
ð1Þ
where v is the modeled viability, t is the time at which the
measurement has been carried out, and l, K, m are the model
parameters. Equivalently, the model can be interpreted such that
each cell in the population has an exponentially distributed
lifetime after the treatment. As rate of the exponential distribution
we then obtain l 1{ 1z x=K ðÞ
m ðÞ
{1   
. In case of dual-specificity
inhibitors (i.e., inhibitors inhibiting more than one target),
sensitivity of both targets might be very distinct. It may happen
that one target is already completely inhibited with the lowest
concentration in the screen. To capture this effect, an offset loff,
loff§0 can be added to the model, leading to the rate
l 1{ 1z x=K ðÞ
m ðÞ
{1   
zloff. Details of the mathematical model
and its derivation are presented in the Supplementary Note S1.
Figure 1A shows the simulated individual lifetime of 1000 cells,
which have been treated with two different compounds.
Compound concentrations increase from the left to the right
panels. Blue and red lines indicate the time of measurement and
data points which are located at the yellow and white area
represent cells which are still viable at the time of measurement
when treated with compound one. Data points falling into the blue
and white areas display viable cells after treatment with compound
two. In case of a non-synergistic and non-antagonistic compound
combinations the lifetime of the cells is given by the smallest
lifetime when treated with either compound (white area).
Translating the idea of ‘‘minimal lifetime’’ into a mathematical
model leads to a product of the two single compound dose
response curves modeled by Eq. (1) as non-synergistic combined
effect (Fig. 1b, blue curve); this concept is compatible with Bliss
independence. A simulation over a relatively small population on
1000 cells revealed that the simulated points closely correspond to
the theoretical curves (Fig. 1b).
With this mathematical model we next sought to distinguish
between synergy and antagonism of compound response curves
derived from high-throughput screening efforts (Fig. 1C). Start-
ing from the high-throughput screening platform dose response
curves from both single compounds as well as their combinations
were determined for a large panel of genetically annotated non-
small cell lung cancer cell lines. Equation (1) is then fitted to the
dose response curve of each single compound screen. This yields
the model parameters l, K, m, from which the curve separating
synergistic from antagonistic compound combinations can be
computed according to Eq. (S10) of the Supplementary Note
S1. For a given compound combination, the difference between
the computed curve and the measurement is then a measure for
synergy or antagonism, respectively. This measure is denoted by
synergy strength. Due to the presence of noise, several different
compound combinations are needed to filter out cell-lines, which
show significant enrichment of synergy strength over different
combinations. To this end, a rank sum approach is used. In order
to account for multiple hypothesis testing the false-discovery rate
(FDR) framework [29] was applied.
Applying the Model for Single Compound Screen of
PI-103 and BIBW-2992
In order to validate the proposed model, Eq. (1), we screened
65 of the 84 non-small cell lung cancer cell lines [9] against the
irreversible EGFR/ERBB2 inhibitor BIBW2992 and the PI3K/
mTOR inhibitor PI-103. We selected 4 out of the 65 cell lines and
fitted the dose response curves to the corresponding data points
(Fig. 2A). We next determined the difference between the
viability predicted by the model and the experimentally deter-
mined values (model residuals). To assess the quality of the model
we computed the median of the residuals over the concentrations
for each compound and cell line (Fig. 2B). For both compounds,
significant outliers are then identified under the assumption that
the medians of the residuals are normally distributed around zero.
Using a 5% level of significance and after correcting for multiple
testing we identified only one outlier: Calu6 screened with PI-103
(FDR q-value=7.6 10
212). However, this outlier can safely be
neglected since it did not distort the following analysis. In
summary, the proposed model fits well to the measured data
and is therefore a suitable basis for the identification of synergistic
compound combinations.
Computing half-maximal-inhibitory concentrations (Eq. (2),
Materials and Methods) for PI-103 and BIBW-2992
(Figure 2C) shows no clear association between the genomic
lesions and the single-agent activity of PI-103 with the used cell
proliferation assay [19]. As expected, in the case of the irreversible
EGFR/ERBB2 inhibitor BIBW-2992, cell lines dependent on
EGFR and ERBB2 signaling (due to the presence of drug-
sensitizing genetic alterations in these genes) are substantially
enriched in the highly sensitive cell lines [30,31].
Application of the Model for Combinational Compound
Screen of PI-103 with BIBW-2992
In order to test the accuracy of our model to detect synergy of
compound combinations we next sought to systematically assess
the viability of cells treated with a combination of the two
compounds. With the EGFR/PI3K signaling cascade being one of
the most frequently mutated pathways in lung cancer, we
speculated that combined inhibition of EGFR- and PI3K/
mTOR-signaling might be effective in our cell line panel of
NSCLC cells. The presence of considerable experimental noise
(Fig. 2B) makes it necessary to test different combinations for the
determination of synergy. Therefore, seven compound dose
combinations of PI-103 and BIBW-2992 were applied for the 65
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separates synergistic from antagonistic combinations, is computed
from the previously determined fits, which serves as basis for the
synergy strength. We next computed this synergy score and
applied hierarchical clustering to the data matrix of the synergy
strength (Fig. 3A). This analysis revealed two distinct groups,
separating cell lines according to synergistic and antagonistic
behavior. To assess which cell lines in those clusters display a
significantly synergistic or antagonistic response to combined
EGFR-PI3K inhibition, we employed a rank sum-based statistical
test (Fig. 3A). Ranks of synergy strength were computed over all
cell lines but for each measured combination separately and
summed over the seven combinations. Next, a statistical test was
derived to test if high or low ranks were enriched. To correct for
multiple testing all p-values were corrected using the false-
discovery rate approach. Resulting q-values are shown in
Fig. 3A, where the horizontal green line indicates the chosen
5% false-discovery rate cutoff. We identified 11 cell lines, for
which combined PI-103/BIBW-2992 treatment was significantly
synergistic. Our analysis revealed that cell lines harboring either
amplification or a mutation in either EGFR or ERBB2 were not
enriched in the fraction of cell lines responding in synergistic
fashion to the combination of both compounds. These results
suggest that inhibition of ERBB-signaling in these cell lines is
already sufficient to effectively shut down survival signaling.
However, no other significant correlation between synergy
strength and genotype could be observed (Fig. 3A).
To further validate our methodological framework, we
compared our results with synergy predictions based on the
combination index method [12,32,33]. While the combination
index yielded a result in only 66% of the screening data analyzed,
our approach yielded robust synergy scores across the entire data
Figure 1. Overview of the model and method to detect synergistic compound combinations. (A) Model based simulation of the lifetime
of 1000 cells after treatment. The x-axis corresponds to the lifetime after treating cells with compound 1 and the y-axis shows the lifetime after
treatment with compound 2. Concentrations of both compounds are increased by a factor of 10 from left to right. Either the vertical blue line in case
of compound 1 or the horizontal red line for compound 2 indicates time of measurement. Thus, the number of viable cells at measurement is given
by the number of data points on the right side of the blue lines (after treatment with compound 1) or above the red line (in case of compound 2).
Distributions of viable and dead cells are displayed by bars at the upper and right side of each panel. Combining both compounds and assuming that
the combination of both compounds is neither synergistic nor antagonistic yields a certain number of viable cells that is represented by dots in the
white area. This notion reflects the fact that the minimal lifetime between the two compounds (x and y-axis) has to be taken for the combination. (B)
Theoretical dose response curves are shown for the previous example. Data points were computed from results of the simulation shown in (A). Even
for the relatively small population of 1000 cells, the simulated data points and the theoretical curve match. (C) Scheme of the procedure to detect
synergistic and antagonistic compound combinations. Starting from a high-throughput compound screen, the model is fitted to all single-agent
measurements. From the fitted model parameters, curves are computed for each combination separating synergy from antagonism. Measured data
of the combination screen are then compared to the computed curves and finally analyzed using a rank-based statistical test.
doi:10.1371/journal.pone.0008919.g001
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PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8919Figure 2. Results obtained from the single-compound screen of PI-103 and BIBW-2992. (A) Kill-curves are exemplarily shown for two
compounds (PI-103 and BIBW-2992) and 4 cell lines. Solid red lines display the fitted model to the measured data shown by black points. (B) Analysis
of the model residuals (i.e., difference between the measurements and the model prediction) for both compounds and each cell line. Shown are the
distributions of the residuals’ medians over the screened concentrations. A statistical test to detect significant outliers reveals that only the cell line
Calu3 when screened against PI-103 is not compatible with the distribution of the median of residuals (FDR q-value=7.6 10
212); highlighted by a red
bar. (C) Profiles of GI50-values for PI-103 and BIBW-2992. GI50-values were computed using the proposed model and sorted according to the
sensitivity of the cell line to the inhibitions: most sensitive cell lines are on the left side and most resistant cell lines are shown on the right side. Colors
symbolize most common genomic alterations in NSCLC. In case of EGFR
mut/amp and ERBB2
mut/amp a genomic alteration can either be a mutation or a
gene copy number amplification ($4 copies are considered as alteration), for MET
amp only amplifications are reported, the remaining alterations,
BRAF
mut, NRAS
mut, KRAS
mut are mutations. For BIBW-2992, asterisks highlight those cell lines, which harbor lesions either in EGFR or ERBB2.
doi:10.1371/journal.pone.0008919.g002
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8919Figure 3. Exploring synergy and antagonism of the compound combination PI-103 with BIBW-2992. (A) Combinations of PI-103 and
BIBW-2992 were screened for all cell lines and the synergy strength score was computed as difference between measured data and the curve
separating synergy from antagonism. Hierarchical clustering clearly classifies the cell lines into two groups according to the algebraic sign of the
synergy strength score (positive: synergy; negative: antagonism). Results of a rank sum-based statistical test mainly reproduce the results from cluster
analysis. Setting the level of significance to a false discovery rate of 5% (horizontal green line) yields 11 cell lines showing synergy. Finally, the
annotation of 8 frequent genomic aberrations indicates that almost all cell lines harboring genomic alterations in ERBB2 family member do not
benefit from the combination. (B) Shown is the relationship between single-agent GI50-values and synergy. All cell lines showing significant synergy
are highlighted by red symbols. Annotating the cell lines with mutation and copy number status of EGFR and ERBB2 (distinguished by quadratic
symbols and triangles) confirms the previous finding that cell lines harboring alterations in EGFR/ERBB2 do not significantly benefit from the
combination in terms of synergy. (C) Shown are the main signaling network compounds downstream EGFR and ERBB2 as well as the targets of BIBW-
2992 and PI-103. Since the PI3K-mTOR pathway is downstream EGFR/ERBB2, cell lines which depend on EGFR/ERBB2-signaling do not benefit from
the combination.
doi:10.1371/journal.pone.0008919.g003
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However, in the fraction of data that could be analyzed by both
methods, synergistic cell lines determined with our method and the
combination index method largely overlapped (Fig. S1). This is
underscored by a regression analysis between the negative-log-
transformed combination index and the synergy strength score
(Fig. S2), which showed a significant positive correlation
(r
2=0.45; p,10
26). The enhanced robustness of our approach
is largely due to the fact that it takes into account the entire dose
response relationship and is not restricted to the behavior of a
single point (Supplementary Note S1).
The observation that combination treatment is not beneficial in
cell lines with oncogenic alterations in EGFR and ERBB2
indicates that there might be a relationship between activity of
the individual compounds and synergy. In order to demonstrate
such a relationship, we plotted the GI50-values of PI-103 against
those of BIBW-2992 and labeled all data points of cell lines with
genetic aberrations in the EGFR/ERBB2 receptor tyrosine kinases
(Fig. 3B). This analysis recapitulated the previous findings that
cell lines, which are primarily dependent on EGFR/ERBB2
signaling (GI50,0.1 mM), do not benefit from the combination of
ERBB/PI3K-pathway inhibition. Remarkably, our findings are in
line with the general topology of the signaling pathways
downstream of EGFR and ERBB2 (Fig. 3C). Since oncogenically
activated EGFR and ERBB2 receptors preferentially signal
through the PI3K pathway [19] combined blockade of those
pathways is not expected to be synergistic for cells depending on
EGFR or ERBB2. In other words, potent inhibition of strong
oncogenic signals upstream is already sufficient to induce apoptosis,
independent of the inhibition of further components downstream
(Fig. 3C). The same seems to be valid for three cell lines with the
lowest PI-103 GI50-values. However, dependency on PI3K-
mTOR signaling was generally less pronounced (expressed by
higher GI50-values) which might be a result of alternative
pathways upstream PI3K such as the mitogen-activated protein
kinase (MAPK) and feedback loops connecting the two pathways
[19]. However, synergistic combinations clustered around a GI50-
value of 1mM for PI-103. We therefore speculate that a supra-
threshold activity of PI3K inhibition is needed to obtain synergy.
In order to provide a deeper characterization of the genotypes,
we extended the previously used genetic annotation with
significant copy number aberrations computed by GISTIC [34].
A complete list of all identified copy number aberrations and the
mutation status of 7 genes is given for the cell lines showing
synergistic behavior in Table S1. Similar to the analysis done in
[9], we performed a k-nearest-neighbor prediction on this data set
and found no significant predictor of synergy (Table S2). The
inability to predict synergy from genetic lesions is probably
hampered by the necessity to restrict the analysis to recurring and
highly focal copy number lesions as identified by GISTIC and the
focus on the most frequent gene mutations in NSCLC.
Discussion
Starting from general considerations about cell viability
measurements, we derived a model for inferring cell survival
curves from high-throughput cell-based screening data [35]. This
model laid the basis for detection of synergy strength of compound
combinations. Here, the central assumption is that the median-
effect equation [12,32,33] is coupled linearly to a cell-killing rate
under treatment. Validation of the model in a panel of 65 lung
cancer cell lines perturbed using PI3K and EGFR/ERBB2
signaling pathway inhibitors revealed general rules of the signaling
pathway topology downstream of genetically altered EGFR and
ERBB2 kinases. Thus, our approach affords analysis of synergy of
compound combinations in high-throughput cell-based screens in
scalable fashion.
Other approaches involving the network structure of complex
biological systems have been proposed [24,35]. Our model has the
advantage of permitting systematic statistical analyses of synergy
employing generic laboratory cellular screening experiments
involving a vast array of genetic cellular backgrounds. Another
major advantage of our model is its stochastic nature describing
the lifetime of cells under treatment. This allows a rigorous
derivation of a synergy score when cells are treated with a
combination of compounds. In fact, we confirmed Bliss indepen-
dence [28] based on this computation but within a solid theoretical
framework.
As application of the proposed analytical framework, we applied
the method to single and combined screens of the PI3K inhibitor,
PI-103 and the EGFR/ERBB2 inhibitor, BIBW-2992. Our model
captured previous findings that genetic alterations in EGFR are
predicting sensitivity of EGFR inhibitors [4,36,37]. Analysis of
synergy between PI-103 and BIBW-2992 revealed that cell lines
dependent on EGFR/ERBB2-signaling do not benefit from the
combination (Fig. 3A, B), which is in line with the network
topology suggesting a preferential linear downstream engagement
of PI3K signaling downstream of oncogenically activated receptor
tyrosine kinases [7,19]. Previous work carried out in transgenic
EGFR and ERBB2-mutant mice showed substantial tumor
regression when mice were treated with a combination of
BIBW-2992 and rapamycin targeting mTOR (or more specifically
TORC1) [30,31]. However, both transgenic alleles in these studies
impair binding of quinazoline-based EGFR inhibitors, thus
resulting in inefficient target inhibition [38]. Thus, adding
downstream inhibition in the setting of incomplete upstream
target inhibition can result in synergy, even though the pathway
itself is linear (Fig. 3C). Here, crosstalk or an upstream branching
into other signaling components can mediate such an effect. In our
study, signaling through the MAPK pathway might substantially
contribute to synergy since there are numerous interconnections
between MAPK and PI3K signaling pathways.
In summary, we introduced a new methodological framework to
detect synergy of compound combinations across a large panel
of cancer cell lines. The analysis of a first combination screen
supported a view of a mostly linear signaling pathway topology
downstream of oncogenically activated EGFR/ERBB2 kinases
[19]. Thus, beyond enabling high-throughput analyses of com-
pound combinations, our approach affords general insights into
pathway functionality and pathway interrelations.
Materials and Methods
Cells
The used cell line collection was previously described in [9].
Cells were routinely controlled for infection with mycoplasm by
MycoAlert (www.cambrex.com) and were treated with antibiotics
according toa previouslypublished protocol [39] incaseof infection.
Cell-Based Screening
All compounds were purchased from commercial suppliers or
synthesized in house, dissolved in DMSO and stored at 280uC.
Cells were plated into sterile microtiter plates using a Multidrop
instrument (http://www.thermo.com) and cultured overnight.
Compounds were then added in serial dilutions. Cellular viability
was determined after 96h by measuring cellular ATP content using
the CellTiter-Glo assay (www.promega.com). Plates were measured
on a Mithras LB940 plate reader (www.bertholdtech.com).
Analysis of Compound Synergy
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Genomic DNA was extracted from cell lines using the
PureGene kit (www.gentra.com) and hybridized to high-density
oligonucleotide arrays (Affymetrix, Santa Clara, CA) interrogating
238,000 SNP loci on all chromosomes except Y, with a median
intermarker distance of 5.2 kb (mean 12.2 kb; http://www.
affymetrix.com). Array experiments were performed according to
manufacturer’s instructions. SNPs were genotyped by the
Affymetrix Genotyping Tools Version 2.0 software. We applied
GISTIC [34] to analyze the data set. The GISTIC algorithm was
run using a copy number threshold of 4 in case of amplifications
and 1 for deletons. To ensure compatibility of the copy number
data with mutation data we dichotomized copy numbers with the
following thresholds: 4 for amplifications and 1 for deletions.
Model Based Computation of GI50-Values
Applying the half-maximal-inhibitory concentration concept
(‘‘GI50-values’’) we set the viability to 50% in Eq. (1); followed by a
few algebraic rearrangements yields the model-based computation
of the GI50-values:
GI50~K
log(2)
lt{log(2)
   1
m if ltwlog(3): ð2Þ
Positivity of the GI50-values is guaranteed by the condition in
Eq. (2). If this condition is not satisfied, no GI50-value exists, i.e.,
the on-target inhibition is to weak to kill enough cells such that a
viability of 50% can be reached.
Data Analysis and Statistics
The model of single-agent kill curves, Eq. (1), are fitted to data.
To this end, a maximum likelihood approach is employed to
estimate the model parameters l, K, m. This requires non-linear
optimization; we chose the Levenberg-Marquardt method for this
optimization [40,41]. P-values where corrected for multiple testing
using the false-discovery-rate approach [29]. The p-value
adjustment as well as the cluster analysis was carried out in R
version 2.7.1 (http://www.R-project.org).
Rank Sum Rest
We decided to employ a rank sum based approach to provide a
statistical measurefor synergy.Thisapproach hasthe advantage that
it also takes prevalence across different cell lines into account and
does not purely rely on the synergy strength. This is an important
and therapeutically relevant property of the statistical test.
Let us consider the synergy strength measure: Sij~Vij{v0ij,
where Vij is the measured viability for the combination i [f1,ncg
and cell line j [f1,nlg. The computed curve separating synergy
from antagonism, given by the product of both single compound
dose response curves (Eq. (S10), Supplementary Note S1), is
denoted by v0ij. Ranks are computed over all cell lines j but for
each combination i separately; resulting in the rank matrix Rij.
Utilizing that the ranks are uniformly distributed leads to the
following variance of the ranks across the cell lines:
s2
i ~
n2
l {1
12
:
Moreover, under the null-hypothesis that there is no association
between the ranks of each combination, the variance of the rank
sum
P nc
i~1
Rij is
s2~
X nc
i~1
s2
i ~
nc(n2
l {1)
12
: ð3Þ
Relating the rank sum to the median is not useful in our case. If,
e.g., Sij is negative for all i and j (i.e., there is no sample showing
synergistic behavior), a median centered rank sum test would
assign a few samples as being synergistic. To derive the test
statistics, which corrects for such an effect, we relate the rank sum
to the rank where the synergy score Sij changes its sign. To this
end, we compute for each concentration i the rank that has the
lowest absolute synergy score
mi~Rik where k~argmin
1ƒjƒnl
jSijj:
Finally, the rank sum statistics we propose to test for synergy is
given by
RSj~s{1 X nc
i~1
Rij{mi
  
~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
12
nc(n2
l {1)
s
X nc
i~1
Rij{mi
  
: ð4Þ
Under the null-hypothesis that there is no association between
the ranks of different concentrations and that the synergy score
fluctuates around zero, the distribution of RSj can be approx-
imated by a standard normal distribution. This approximation is
asymptotically (j??) correct and used in our analysis.
Supporting Information
Supplementary Note S1 Analysis of compound synergy in
high-throughput cellular screens by population-based lifetime
modeling.
Found at: doi:10.1371/journal.pone.0008919.s001 (0.08 MB
PDF)
Figure S1 Comparison between the combination index method
and the method we propose. Shown is the clustered matrix of the
synergy strength measure, as in Fig. 3A, together with the
combination index. Significantly synergistic cell lines which where
detected with our method are highlighted by red bars. Missing
bars indicate that for those cell lines the computation of the
combination index was not possible.
Found at: doi:10.1371/journal.pone.0008919.s002 (0.69 MB
PDF)
Figure S2 Correlation analysis between both methods. To adapt
the scale of both measures, we performed a transformation of the
combination index using the negative logarithm. The regression
line is displayed by the straight red line. Moreover, we found a
significant positive correlation (r
2=0.45; p,10
26), which confirms
that both methods follow the same trend.
Found at: doi:10.1371/journal.pone.0008919.s003 (0.12 MB
PDF)
Table S1 Genomic annotation of all 11 cell lines showing
synergistic behavior. Significant copy number regions were
identified using GISTIC. To assure comparability with mutation
data, copy numbers were dichotomized with the following
thresholds: 4 in case of amplifications and 1 for deletions.
Found at: doi:10.1371/journal.pone.0008919.s004 (0.03 MB
PDF)
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method, Fishers exact test and t-test are displayed; here, only p-
values smaller than 5% are shown. The Youden-Index (i.e.,
sensitivity+specificity-1) of zero indicates that the result has no
predictive power.
Found at: doi:10.1371/journal.pone.0008919.s005 (0.02 MB
PDF)
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